Greg Harrison
Stock Analyst at B of A Securities
(1.87)
# 2,881
Out of 4,820 analysts
80
Total ratings
31.75%
Success rate
-8.04%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Upgrades: Neutral | $314 | $292.09 | +7.50% | 2 | Apr 21, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $30 → $31 | $17.46 | +77.60% | 3 | Apr 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $18.29 | +69.49% | 9 | Apr 1, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $338 → $342 | $250.21 | +36.69% | 5 | Mar 31, 2025 | |
| LQDA Liquidia | Maintains: Sector Outperform | $30 → $34 | $13.94 | +143.90% | 5 | Mar 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Sector Outperform | $40 | $19.49 | +105.23% | 5 | Mar 10, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Sector Outperform | $51 → $52 | $7.32 | +610.38% | 4 | Mar 3, 2025 | |
| IRON Disc Medicine | Maintains: Sector Outperform | $73 → $75 | $45.30 | +65.56% | 4 | Mar 3, 2025 | |
| GERN Geron | Maintains: Sector Outperform | $6 → $4 | $1.41 | +183.69% | 2 | Feb 27, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $49 → $52 | $36.13 | +43.92% | 5 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $433 → $450 | $491.62 | -8.47% | 5 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $44 → $41 | $14.25 | +187.72% | 5 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $53 → $75 | $29.55 | +153.81% | 4 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $60 | $23.60 | +154.24% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $6.18 | +191.50% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $22 | $7.75 | +183.87% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $13 → $15 | $1.53 | +880.39% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $8.20 | +1,009.76% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $9.57 | +25.39% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.78 | +92.28% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $13.24 | +194.56% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $7.34 | -59.13% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $4.85 | +1,343.30% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $8 | $29.20 | -72.60% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $18.39 | +193.72% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 → $6 | $0.78 | +667.36% | 5 | Mar 14, 2022 |
United Therapeutics
Apr 21, 2025
Upgrades: Neutral
Price Target: $314
Current: $292.09
Upside: +7.50%
Apellis Pharmaceuticals
Apr 2, 2025
Maintains: Sector Perform
Price Target: $30 → $31
Current: $17.46
Upside: +77.60%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $18.29
Upside: +69.49%
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Sector Outperform
Price Target: $338 → $342
Current: $250.21
Upside: +36.69%
Liquidia
Mar 20, 2025
Maintains: Sector Outperform
Price Target: $30 → $34
Current: $13.94
Upside: +143.90%
Beam Therapeutics
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $19.49
Upside: +105.23%
Rocket Pharmaceuticals
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $51 → $52
Current: $7.32
Upside: +610.38%
Disc Medicine
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $45.30
Upside: +65.56%
Geron
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $6 → $4
Current: $1.41
Upside: +183.69%
BridgeBio Pharma
Feb 21, 2025
Maintains: Sector Outperform
Price Target: $49 → $52
Current: $36.13
Upside: +43.92%
Feb 11, 2025
Maintains: Sector Perform
Price Target: $433 → $450
Current: $491.62
Upside: -8.47%
Jan 16, 2025
Maintains: Sector Outperform
Price Target: $44 → $41
Current: $14.25
Upside: +187.72%
Dec 9, 2024
Maintains: Sector Outperform
Price Target: $53 → $75
Current: $29.55
Upside: +153.81%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $60
Current: $23.60
Upside: +154.24%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $6.18
Upside: +191.50%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $22
Current: $7.75
Upside: +183.87%
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $1.53
Upside: +880.39%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $8.20
Upside: +1,009.76%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $9.57
Upside: +25.39%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.78
Upside: +92.28%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $13.24
Upside: +194.56%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $7.34
Upside: -59.13%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $4.85
Upside: +1,343.30%
Jun 8, 2022
Upgrades: Neutral
Price Target: $8
Current: $29.20
Upside: -72.60%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $18.39
Upside: +193.72%
Mar 14, 2022
Downgrades: Underperform
Price Target: $18 → $6
Current: $0.78
Upside: +667.36%